Cargando…
Safety evaluation of a recombinant plasmin derivative lacking kringles 2–5 and rt-PA in a rat model of transient ischemic stroke
BACKGROUND: Tissue type plasminogen activator is the only approved thrombolytic agent for the treatment of ischemic stroke. However, it carries the disadvantage of a 10-fold increase in symptomatic and asymptomatic intracranial hemorrhage. A safer thrombolytic agent may improve patient prognosis and...
Autores principales: | Crumrine, R Christian, Marder, Victor J, Taylor, G McLeod, LaManna, Joseph C, Tsipis, Constantinos P, Novokhatny, Valery, Scuderi, Philip, Petteway, Stephen R, Arora, Vikram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464715/ https://www.ncbi.nlm.nih.gov/pubmed/22591588 http://dx.doi.org/10.1186/2040-7378-4-10 |
Ejemplares similares
-
Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model
por: Crumrine, R Christian, et al.
Publicado: (2011) -
Potential Role of Kringle-Integrin Interaction in Plasmin and uPA Actions (A Hypothesis)
por: Takada, Yoshikazu
Publicado: (2012) -
l-Palmitoylcarnitine potentiates plasmin and tPA to inhibit thrombosis
por: Yang, Juan, et al.
Publicado: (2023) -
Phase 2, randomized, open-label study on catheter-directed thrombolysis with plasmin versus rtPA and placebo in acute peripheral arterial occlusion
por: Comerota, Anthony J., et al.
Publicado: (2019) -
Miguel Llinás and the Structure of the Kringle Fold
por: Patthy, Laszlo
Publicado: (2021)